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Abstract
Background:  Previous research indicated that women are more vulnerable than men to adverse
psychological consequences of weight gain. Other research has suggested that weight gain experienced
during antipsychotic therapy may also psychologically impact women more negatively. This study assessed
the impact of acute treatment-emergent weight gain on clinical and functional outcomes of patients with
schizophrenia by patient gender and antipsychotic treatment (olanzapine or haloperidol).
Methods: Data were drawn from the acute phase (first 6-weeks) of a double-blind randomized clinical
trial of olanzapine versus haloperidol in the treatment of 1296 men and 700 women with schizophrenia-
spectrum disorders. The associations between weight change and change in core schizophrenia symptoms,
depressive symptoms, and functional status were examined post-hoc for men and women and for each
medication group. Core schizophrenia symptoms (positive and negative) were measured with the Brief
Psychiatric Rating Scale (BPRS), depressive symptoms with the BPRS Anxiety/Depression Scale and the
Montgomery-Asberg Depression Rating Scale, and functional status with the mental and physical
component scores on the Medical Outcome Survey-Short Form 36. Statistical analysis included methods
that controlled for treatment duration.
Results:  Weight gain during 6-week treatment with olanzapine and haloperidol was significantly
associated with improvements in core schizophrenia symptoms, depressive symptoms, mental functioning,
and physical functioning for men and women alike. The conditional probability of clinical response (20%
reduction in core schizophrenia symptom), given a clinically significant weight gain (at least 7% of baseline
weight), showed that about half of the patients who lost weight responded to treatment, whereas three-
quarters of the patients who had a clinically significant weight gain responded to treatment. The positive
associations between therapeutic response and weight gain were similar for the olanzapine and haloperidol
treatment groups. Improved outcomes were, however, more pronounced for the olanzapine-treated
patients, and more olanzapine-treated patients gained weight.
Conclusions:  The findings of significant relationships between treatment-emergent weight gain and
improvements in clinical and functional status at 6-weeks suggest that patients who have greater
treatment-emergent weight gain are more likely to benefit from treatment with olanzapine or haloperidol
regardless of gender.
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Background
Because antipsychotic drugs are considered the core treat-
ment modality for schizophrenia [1] the differences
among antipsychotics in terms of effectiveness, safety, and
tolerability have expectedly become a topic of growing
clinical and research interest [2]. The differences among
antipsychotics in adverse events have garnered particular
interest, with treatment-emergent weight gain becoming a
focal point of attention and concern because weight gain
can be associated with medical conditions such as type II
diabetes, hypertension, and coronary artery disease [3].
Previous research has shown that there are variations with
respect to the magnitude and the course of typical weight
gain experienced during treatment with different antipsy-
chotics [4]. Generally, the first generation antipsychotics,
such as haloperidol, are associated with less weight gain
than the second-generation antipsychotics. The newer
atypical agents vary such that clozapine and olanzapine
are associated with the greatest potential for weight gain,
followed by risperidone, quetiapine, ziprasidone, [5] and
aripiprazole.
Although most of the literature on treatment-emergent
weight gain tends to focus on this event as adverse, a grow-
ing body of research has demonstrated a significant link
between beneficial therapeutic response and treatment-
emergent weight gain. With the exception of a few studies
that failed to find an association between weight gain and
better clinical outcome [6-9], most studies, primarily on
clozapine, suggest an association between weight gain
and better clinical outcome [10-19]. This expanding body
of evidence augments studies on first-generation antipsy-
chotics predating the introduction of atypical antipsy-
chotics by about 30 years, also suggesting a link between
weight gain and improved therapeutic response [20-22].
One study [17] reported mixed findings, where the associ-
ation between treatment-emergent weight gain and clini-
cal outcome was found for patients treated with clozapine
and olanzapine, but not with risperidone or haloperidol,
suggesting that this phenomenon may be specific to par-
ticular antipsychotics.
The study of gender differences in the relationship
between treatment-emergent weight gain and therapeutic
response has gained limited attention and provided con-
flicting results. A brief report on weight gain during cloza-
pine therapy indicated that greater weight gain was
associated with clinical improvement among women, but
not among men [13]. In contrast, a more extensive analy-
sis [16] demonstrated that clozapine-emergent weight
gain predicted improvement in psychopathology among
both men and women. It is unclear if there are gender dif-
ferences in the association between treatment-emergent
weight gain and therapeutic response, and if such gender
differences exist, whether they are limited to a specific
antipsychotic such as clozapine.
Women in the general population appear to be vulnerable
to the adverse emotional and psychosocial consequences
of weight gain. For women, obesity has been linked to
lower life satisfaction, increased social isolation [23], and
lower levels of psychological and physical functioning
[24-26]. Compared to men, women are more likely to per-
ceive themselves as overweight [27], to diet [28], and to
participate in weight loss programs [28]. Based on gener-
alizations from studies on women in the general popula-
tion, several authors have speculated that antipsychotic-
emergent weight gain will be similarly accompanied by
negative psychological consequences [29-31], which will
negatively impact women's response to antipsychotic
therapy. However, it is unclear if women who gain weight
during treatment with antipsychotics tend to experience
adverse emotional consequences similar to those noted
among women who gain weight in the general popula-
tion. It is also unclear whether the association between
treatment-emergent weight gain and clinical response dif-
fers by patient gender and by type of antipsychotic.
The primary objective of this study was to expand on prior
research and investigate whether the relations between
acute weight gain during antipsychotic therapy and treat-
ment outcomes differ based on patient gender and the
specific antipsychotic used in the treatment regimen,
olanzapine or haloperidol. This study also aimed to
broaden the definition of therapeutic response by extend-
ing beyond positive and negative symptoms of schizo-
phrenia to depressive symptoms and levels of mental and
physical functioning, because these domains tend to dete-
riorate with weight gain among women in the general
population.
Methods
Subjects and study design
We used data of 1296 men and 700 women who partici-
pated in a randomized, double-blind, multi-center, clini-
cal trial comparing olanzapine to haloperidol [32].
Participants met DSM-III-R criteria for schizophrenia
spectrum disorders (schizophrenia, schizoaffective disor-
der, or schizophreniform disorders), and were required to
have a total score on the Brief Psychiatric Rating Scale
(BPRS) [33] of ≥ 18 and/or intolerance to current antipsy-
chotic therapy, excluding haloperidol. Following
approval of institutional review boards, written informed
consent was obtained from all participants.
Participants were randomly assigned in 2:1 ratio (2 olan-
zapine subjects for each haloperidol subject). Although
randomization was not stratified on gender or any other
patient characteristics, it resulted in a 2:1 ratio for malesBMC Psychiatry 2005, 5:3 http://www.biomedcentral.com/1471-244X/5/3
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(870/426) and for females (426/233). The olanzapine
group (N = 1337) included 467 women and 870 men,
and the haloperidol group (N = 659) was comprised of
233 women and 426 men.
Participants were randomly assigned to olanzapine, 5 to
20 mg/day, or haloperidol, 5 to 20 mg/day. The type of
antipsychotic medication used prior to enrollment was
not assessed in the current study, but the likelihood of
previous treatment with an atypical antipsychotic drug
was very low, because the study was initiated in 1994
when only clozapine was available in some of the sites.
Further, randomization worked for patient and illness
characteristics [32], and there is no reason to expect that
the randomization did not work for other characteristics
such as type of prior antipsychotic medication.
We used data from the acute phase, the first 6 weeks of the
study, for several reasons. First and foremost, this study
was a 6-week randomized double blind clinical trial with
a 46-week "responder maintenance period", in which
only patients who responded to the acute 6-week treat-
ment per predetermined response criteria were eligible to
continue. Consequently, the study design did not permit
a longer-term analysis on the link between weight gain
and improvement because only patients who improved
during the first 6-weeks phase were followed-up for a
longer time period. Second, the 6-week period represents
a relevant time frame often used in clinical practice to
determine treatment outcome and decide on treatment
discontinuation [15]. For many clinicians the initial 6-
weeks of antipsychotic therapy is a minimal time period
in which to critically evaluate how patients are responding
to a new course of therapy. Third, the rate of weight gain
previously reported on clozapine was greatest in the first
6 weeks and slowed thereafter [16], such that the increase
between 6 weeks and 6 months was equivalent in magni-
tude between baseline and 6 weeks. This observation fur-
ther enhanced the relevance of studying this
phenomenon during the first 6-weeks of treatment. And
lastly, the short duration of the current study is compara-
ble to most previous studies of antipsychotic-emergent
weight gain and clinical improvement, thus enabling
more direct comparisons between the present and the pre-
vious findings.
During the 6-week acute phase, the mean modal dose was
13.2 mg/day (SD = 5.8) for olanzapine and 11.8 mg/day
(SD = 5.6) for haloperidol. There were no discontinua-
tions due to weight gain as an adverse event for any treat-
ment group during the 6-week study period, and the rate
of discontinuation for any cause was similar for women
(62.7%) and men (60.8%), with a significantly smaller
proportion of the patients in the olanzapine group
(33.5%) than in the haloperidol group (53.2%, p < .001).
In addition, the percentage of patients who discontinued
treatment because of an adverse event or a lack of efficacy
was significantly higher in the haloperidol group than in
the olanzapine group. Further details on the parent study
design and primary findings are available elsewhere [32].
Measures
This investigation used measures of positive and negative
symptoms ("core schizophrenia symptoms"), depressive
symptoms, functional status, and body weight. Core
symptoms of schizophrenia were assessed by the Positive
Symptom and the Negative Symptom subscales on the
BPRS (scored on a scale of 0–6) extracted from the Posi-
tive and Negative Syndrome Scale (PANSS) [34]. Levels of
depressive symptoms were assessed by the Depression/
Anxiety subscale in the BPRS and total score on the Mont-
gomery-Asberg Depression Rating Scale (MADRS) [35].
The Physical and the Mental Component scores on The
Medical Outcome Survey – Short Form 36 (SF-36) [36]
assessed physical and mental functioning. The SF-36 pro-
vides scores on eight functional scales: physical function-
ing, role limitations due to physical functioning, bodily
pain, general health, social functioning, role limitations
due to emotional problems, vitality and mental health.
The first four scales can be summarized into a Physical
Component Score (PCS) and the latter four constitute the
Mental Component Score (MCS). PCS and MCS are often
used alone because they account for 85% of reliable vari-
ance of the eight SF-36 domains, without losing informa-
tion. It is notable that unlike the symptom measures,
which were clinician-rated scales, the SF-36 is a patient-
reported measure that provides patients' subjective
appraisal of current functional status independently of cli-
nicians' perceptions. Weight change (in kilograms) was
measured from baseline to 6 weeks, or to endpoint for
patients who dropped out of the study prior to the 6-week
visit. BMI was calculated as weight in kilograms divided
by the square of height in meters (BMI = kg/m2).
To enhance comparability of findings on different meas-
ures, the clinical measures were all standardized to z-
scores. For the BPRS Core Symptoms, MADRS, and BPRS
Anxiety and Depressive Subscale, this was done by sub-
tracting the measure's overall mean and dividing by the
measure's standard deviation at baseline. A single meas-
ure of depressive symptoms was calculated as the average
of the standardized MADRS and BPRS Anxiety and
Depressive Subscale. If a score was missing on either
depression measure, the score on the available measure
was used. The two depression measures were pooled
because each is an independent and valid estimate of
patients' level of depressive symptoms, and aggregating
them should provide the best and most comprehensive
estimate of depressive symptoms. Additionally, the pool-
ing helped minimize loss of data, which are assumed notBMC Psychiatry 2005, 5:3 http://www.biomedcentral.com/1471-244X/5/3
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to be missing at random. The SF-36 Physical and Mental
Component scores were converted from T-Scores to z-
scores.
Statistical analysis
Baseline comparisons used independent samples t-tests
for continuous variables and chi-square tests for categori-
cal variables. Effects of treatment and gender on inde-
pendent variables were assessed using ANCOVA, with the
baseline score as well as the number of weeks in the study
as covariates. The relationship between change in weight
and change in each outcome variable was assessed using
separate multiple linear regression analyses, each with
corresponding clinical change score as a dependent varia-
ble, the corresponding baseline score and number of
weeks in the study as covariates, and the following inde-
pendent variables: weight change, treatment group assign-
ment, and gender. In an additional analysis, the
interactions of these three independent variables were
added to the regression models.
The analyses included measures from baseline and the 6-
week visit. Missing data were handled by carrying forward
the last observation for all patients with at least one post-
baseline assessment. All analyses were performed using
the Statistical Package for the Social Sciences (SPSS) ver-
sion 11.0.
Results
Baseline characteristics
Relative to men, women were older, more likely to be
Caucasians, were more likely to be overweight or obese,
had less severe positive symptoms, lower levels of physical
functioning, and had higher levels of depressive symp-
Table 1: Gender differences at baseline*
All patients Women Men
Characteristic N = 1996 N = 700 N = 1296 P
Demographics
Age 38.6 (11.4) 40.9 (12.8) 37.3 (10.4) <0.001
Race 0.013
Caucasian 1600 (80.2%) 587 (83.9%) 1013 (78.2%) 0.002
African descent 220 (11.0%) 67 (9.6%) 153 (11.8%) 0.128
Hispanic 83 (4.2%) 19 (2.7%) 64 (4.9%) 0.018
Other 93 (4.7%) 27 (3.9%) 66 (5.1%) 0.211
Diagnosis <0.001
Schizophrenia 1658 (83.1%) 526 (75.1%) 1132 (87.3%) <0.001
Schizoaffective disorder 300 (15.0%) 157 (22.4%) 143 (11.0%) <0.001
Schizophreniform disorder 38 (1.9%) 17 (2.4%) 21 (1.6%) 0.207
Core schizophrenia symptoms
BPRS total 33.4 (10.7) 33.5 (11.2) 33.3 (10.5) 0.660
BPRS positive 10.3 (4.1) 10.0 (4.1) 10.5 (4.0) 0.017
BPRS negative 6.7 (3.3) 6.7 (3.4) 6.7 (3.3) 0.791
Depressive symptoms
MADRS 16.6 (8.8) 17.3 (9.3) 16.3 (8.5) 0.031
BPRS anxiety and depression 7.5 (3.8) 8.0 (3.9) 7.3 (3.8) <0.001
Functional status
SF-36 physical component 43.6 (13.0) 41.4 (14.0) 44.5 (12.5) 0.004
SF-36 mental component 34.6 (12.4) 34.6 (12.9) 34.6 (12.2) 0.958
Weight
Weight, kg 76.8 (17.1) 70.2 (16.4) 80.4 (16.3) <0.001
BMI 26.0 (5.2) 26.5 (5.8) 25.8 (4.9) 0.007
BMI level <0.001
Underweight to average (BMI < 25) 930 (48.9%) 319 (47.6%) 611 (49.6%) 0.418
Overweight (BMI ≥ 25 and < 30) 609 (32.0%) 191 (28.5%) 418 (33.9%) 0.016
Obese (BMI ≥ 30) 364 (19.1%) 160 (23.9%) 204 (16.5%) <0.001
* Data are presented as Mean (SD) or N (%).
P-values refer to differences between women and men.BMC Psychiatry 2005, 5:3 http://www.biomedcentral.com/1471-244X/5/3
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toms (Table 1). Women were also more likely to be diag-
nosed with a schizoaffective disorder and less likely to be
diagnosed with schizophrenia. At baseline, the weight and
BMI of the haloperidol-treated women and men, were sig-
nificantly greater than the weight and BMI of olanzapine-
treated women and men (Table 2). Further, men in either
medication group weighed significantly more than
women at baseline, on the average, and their mean base-
line BMI was significantly lower than that of women.
Weight gain by treatment group and gender
In order to illustrate the differences in weight gain by
treatment group and gender, the patients were grouped
into thirds based on their percentage of change in weight
from baseline. Approximately one third of all patients
(29.8%) lost weight (any decrease), one third (36.6%)
had relatively stable weight (0% to <3% increase), and
one-third (33.6%) gained weight (≥ 3% increase). The
corresponding mean weight changes in kilograms were -
2.1 kg, 0.9 kg, and 4.6 kg, for lost, stable, and increased
weight groups, respectively. Figure 1 demonstrates that
men and women had a similar weight gain pattern within
each treatment group, and that 59% of olanzapine-treated
patients and 82% of haloperidol-treated patients either
lost weight or maintained stable weight. Further, 17.6% of
the haloperidol treatment group and 41.4% of the olanza-
pine-treated patients gained at least 3% of their baseline
body weight. Compared to the haloperidol-treated
patients, the olanzapine treatment group had a greater
increase in absolute weight (0.3 kg vs. 2.0 kg, F(1,1901) =
122.0, p < 0.001) and a significantly greater proportion of
patients with a potentially clinically meaningful weight
gain, defined as an increase of at least 7% from baseline
body weight (3.0% vs. 13.6%, χ2(1, N = 1913) = 51.8, p <
0.001).
Compared to women, men experienced greater increases
in absolute weight (0.9 kg vs.1.5 kg F(1,1901) = 17.3, p <
0.001), were more likely to experience greater increases in
BMI (0.35 vs. 0.48; F(1,1889) = 5.8, p = 0.016), and were
more likely to have an increase of at least 7% from base-
line body weight (8.1% vs.11.2%; χ2(1, N = 1913, p =
0.032). Within the olanzapine treatment group, but not
the haloperidol treatment group, significantly more men
than women experienced a potentially clinically meaning-
ful weight gain (11.0% vs.15.0%; χ2(1, N = 1286) = 4.0, p
= 0.045 for women and men in the olanzapine treatment
group, and 2.3% vs. 3.5%; χ2(1, N = 627) = 0.7, p = 0.40,
for women and men in the haloperidol treatment group).
Outcomes by treatment group and gender
Table 2 presents the outcome measures and BMI by gen-
der and by treatment group at baseline and endpoints. As
previously documented in the parent study [32], there
were treatment effects on these outcome measures such
that olanzapine-treated patients showed greater improve-
ments than the haloperidol treatment group. There were
no gender effects for any of the clinical (core symptoms of
schizophrenia, depressive symptoms) and functional out-
come measures (mental and physical functioning).
Table 2: Outcomes by gender and treatment group
Women Men
Olanzapine Haloperidol Olanzapine Haloperidol
Outcome measure Baseline Endpoint Baseline Endpoint Baseline Endpoint Baseline Endpoint
Core symptoms
BPRS positive 10.1 (4.0) 6.5 (4.8) 9.9 (4.3) 6.9 (4.4) 10.3 (4.1) 7.0 (4.6) 10.7 (4.0) 8.0 (4.6)
BPRS negative* 6.6 (3.3) 4.4 (3.1) 6.8 (3.4) 5.5 (3.3) 6.7 (3.2) 4.8 (2.9) 6.8 (3.5) 5.5 (3.2)
Depressive symptoms
MADRS* 17.8 (9.6) 11.0 (9.3) 16.1 (8.6) 13.5 (10.7) 16.0 (8.4) 10.5 (7.7) 17.0 (8.7) 13.7 (9.4)
BPRS anxiety & depression* 8.1 (3.8) 5.0 (4.0) 7.8 (4.1) 6.0 (4.3) 7.1 (3.7) 4.5 (3.6) 7.7 (3.9) 5.7 (3.9)
Functioning
SF-36 mental component* 34.7 (13.1) 41.8 (12.1) 34.2 (12.4) 36.5 (13.0) 34.6 (12.4) 40.6 (12.0) 34.7 (11.7) 37.8 (12.3)
SF-36 physical component* 41.3 (14.3) 45.0 (13.9) 41.9 (13.5) 42.1 (13.8) 44.7 (12.2) 48.7 (11.6) 43.9 (13.2) 45.4 (13.1)
Weight
Weight, kg* † 68.9 (15.5) 70.5 (15.8) 72.6 (17.8) 72.4 (17.6) 80.3 (15.9) 82.5 (16.2) 80.7 (17.1) 81.0 (17.4)
BMI* † 2 6 . 1  ( 5 . 4 )2 6 . 7  ( 5 . 5 )2 7 . 2  ( 6 . 6 )2 7 . 1  ( 6 . 5 )2 5.8 (4.8) 26.5 (4.9) 25.7 (5.0) 25.8 (5.0)
* Therapy effect (p < .05), reflecting significant differences between olanzapine and haloperidol-treated patients at baseline.
† Gender effect (p < .05), reflecting significant differences between women and men on weight parameters within each treatment group at baseline, 
and between women and men when combined baseline values across treatment groups.BMC Psychiatry 2005, 5:3 http://www.biomedcentral.com/1471-244X/5/3
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Outcomes, weight change, and gender
To assess the potential effects of gender on the relation-
ship between outcomes and weight change we performed
a set of regression analyses predicting change in each of
the outcome variables (i.e., Core symptoms of schizo-
phrenia, depressive symptoms, gender, and the interac-
tion of these variables). The results indicated that gender
was not a significant variable (i.e., the following compo-
nents were not significant in any of the analyises: gender,
gender by weight change, gender by treatment group, and
gender by treatment group by weight change). Therefore,
gender was dropped from subsequent analyses.
Since men and women were not found to significantly dif-
fer on any of the clinical outcome measures and had a
similar pattern of weight gain within each treatment
group, we examined the association between weight
change and change in treatment outcomes for all patients
within each treatment group. Regression analyses demon-
strated that for both olanzapine and haloperidol-treated
patients, increases in weight were significantly associated
with improvements in core schizophrenia symptoms, (B =
-0.038, t(1899) = 5.6, p < 0.001), in depressive symptoms
(B = -0.030, t(1899) = 5.3, p < 0.001), in mental function-
ing (B = 0.026, t(700) = 2.0, p = 0.047), and in physical
Percentage of patients with different levels of weight change by gender and medication Figure 1
Percentage of patients with different levels of weight change by gender and medication. Patients were placed in 3 equal groups 
based on their percent change in weight: "Lost" indicates any weight loss, "Stable" indicates ≥ 0% to <3% weight gain, and 
"Gained" indicates ≥ 3% weight gain. Olanzapine treatment group (N = 1337; 870 men, 467 women); Haloperidol treatment 
group (N = 659, 426 men, 233 women).
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functioning (B = 0.028, t(700) = 2.3, p = 0.021). Because
level of depressive symptoms was based on two depres-
sion measures, the MADRS and the BPRS depression/anx-
iety subscale, we repeated the analysis using each of these
measure separately. Results were unchanged.
The regression coefficients (B's) indicated that every one-
kilogram increase in weight at 6-weeks was associated
with approximately 0.03 standard deviations improve-
ment in each clinical outcome parameter, when control-
ling for the effects of treatment group, gender, treatment
group-gender interaction, baseline weight, the corre-
sponding baseline outcome measure, and the number of
weeks in the study.
In order to graphically illustrate the findings, the patients
were grouped into thirds based on their percent change in
weight as described above, resulting in lost, stable, and
increased weight groups. Figure 2 demonstrates the simi-
larity in the relationships between weight changes and
changes in the four treatment outcome variables for the
olanzapine and haloperidol treatment groups.
Consistent with a prior analytical approach by Czobor
and colleagues [17], we also performed analyses
(ANCOVA, controlling for baseline weight and weeks in
the study) that specifically contrasted patients who dem-
onstrated clinical improvement (reduction in BPRS Core
Symptoms > 20%) with those who deteriorated by any
amount. On core symptoms, improved olanzapine
patients gained 2.49 kg, compared with 1.42 kg for those
who deteriorated (F(1,1278) = 14.7, p < 0.001). Improved
patients on haloperidol gained 0.08 kg while those who
deteriorated lost 0.44 kg (F(1, 617) = 2.9, p = 0.087). In
order to directly compare current findings with those pre-
viously reported by Czobor and associates, we repeated
the analysis using their analytical variables (absolute
weight change (kg) and PANSS total score), while
covarying baseline bodyweight and baseline PANSS total
score. This analysis demonstrated that improved patients
on olanzapine gained 2.37 kg, compared with 0.59 kg for
those who deteriorated (F(1,1278) = 53.1, p < 0.001).
Improved patients on haloperidol gained 0.15 kg, while
deteriorated patients on haloperidol lost 0.55 kg
(F(1,618) = 6.7, p = 0.010). Results were similar when
also controlling for weeks in the study. The partial corre-
lations between weight gain (kg) and therapeutic
response as measured by the PANSS total score (control-
ling for baseline weight, baseline PANSS total score, and
weeks of treatment) were statistically significant for the
olanzapine and haloperidol treatment groups (partial r =
-0.15, N = 1279, p < 0.001 for olanzapine; partial r = -
0.11, N = 618, p = 0.006 for haloperidol). When using the
Czobor and associates method (controlling only for base-
line weight and baseline PANSS total score), the partial
correlations were more disparate across treatment groups
(partial r = -0.24, N = 1280, p < 0.001 for olanzapine; par-
tial r = -0.10, N = 619, p = 0.013 for haloperidol), high-
lighting the importance of controlling for weeks of
treatment. These correlations were similar in direction but
of smaller magnitude than the partial correlations
reported by Czobor and associates (partial r = -0.57, df =
37, p < 0.001 for olanzapine; partial r = - 0.30, df = 35, p
= 0.060 for haloperidol).
Although weight gain was identified as a prognostic
marker of therapeutic response for both treatment groups,
it was unclear if this marker is stronger for the olanzapine
than the haloperidol treatment group because the olanza-
pine-treated patients had greater weight gain and greater
therapeutic improvements compared to the haloperidol
treatment group. To address this question, we calculated
the conditional probability of clinical response, defined
as reduction in BPRS core symptoms > 20%, given that the
patient experienced various amounts of weight gain on
olanzapine and on haloperidol. Results in Table 3 dem-
onstrate that weight gain was a similar prognostic indica-
tor for each treatment group, as patients who gained more
weight were significantly more likely to respond to treat-
ment for both treatment groups. About half of the patients
who lost weight responded to treatment, whereas three-
quarters of patients who had a clinically significant weight
gain (≥7%) responded to treatment.
Discussion
Like women in the general population, women with
schizophrenia were more likely to be obese [25],
depressed [37], and to physically function at a poorer
level than men [26]. Despite these similarities, which
would be expected to bode poorly for the effects of acute
weight gain on women's treatment outcomes, women and
men who gained weight during antipsychotic therapy
demonstrated significant improvements on core schizo-
phrenia symptoms, depressive symptom, and mental and
physical level of functioning. Overall, weight gain was
found to be linked to better clinical response among men
and women treated with olanzapine or haloperidol. This
link impacted olanzapine-treated patients more than
those treated with haloperidol because improved clinical
and functional outcomes were more pronounced for the
olanzapine-treated patients, who were also more likely to
experience weight gain than patients treated with
haloperidol. The current study adds to the literature by
demonstrating a positive association between treatment-
emergent weight gain and better clinical outcomes that
extends beyond positive and negative symptoms to
depressive symptoms and functional status. Depressive
symptoms in schizophrenia are known to be a distinctive
clinical dimension of prognostic significance [38] that is
associated with compromised quality of life [39],BMC Psychiatry 2005, 5:3 http://www.biomedcentral.com/1471-244X/5/3
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increased risk of psychotic relapse [40], suicidal tenden-
cies, work impairment, lower activity, worse daily func-
tioning, and poorer life satisfaction [41]. In this study,
weight gain during antipsychotic therapy was linked to
improvements in both core symptoms of schizophrenia
and in depressive symptoms, two distinct and clinically
meaningful dimensions of outcome in the treatment of
schizophrenia.
Current findings are consistent with previous research
[10-19] and provide further support to the hypothesis
[16] that a positive link between treatment-emergent
weight gain and improved clinical response may be a gen-
eralized phenomenon across antipsychotic medications.
Although a recent study [17] demonstrated this phenom-
enon for clozapine and olanzapine-treated patients but
not in the haloperidol or risperidone treatment groups,
Change in outcomes by change in weight and treatment group for all patients Figure 2
Change in outcomes by change in weight and treatment group for all patients. Patients were grouped in thirds based on their 
percent change in weight: "Lost" indicates any weight loss, "Stable" indicates 0% to <3% weight gain, and "Gained" indicates 
weight gain of 3% or more. "Depression" as measured by the MADRS or BPRS anxiety and depression scale. "Schizophrenia 
Symptoms" as measured by the BPRS positive symptoms and BPRS negative symptoms scales. "Physical Functioning" as meas-
ured by the SF-36 physical component score. "Mental Functioning" as measured by the SF-36 mental component score. Error 
bars represent 95% confidence intervals. 
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examination of its findings revealed great similarity to the
current results, with a moderate association between
weight gain and therapeutic response for the haloperidol
treatment group despite a small sample size. Interestingly,
the size of the effects reported by Czobor and associates
(partial correlations of -0.57 for olanzapine and -0.30 for
haloperidol) were numerically larger than those found in
the current study (partial correlations of -0.24 for olanza-
pine and -0.10 for haloperidol). Our study supports the
findings of Czobor and associates but with sufficient sta-
tistical power to produce statistically significant results for
both the olanzapine and the haloperidol treatment
groups.
Although the current results are consistent with those
reported in a number of previous prospective studies, our
findings are incongruent with two retrospective surveys.
In the more recent study [42], self-administered surveys
were distributed to schizophrenia patients through
chapters of the National Alliance for the Mentally Ill to
assess their perceptions about the negative impact of
treatment-emergent weight gain on psychosocial func-
tioning. The authors concluded that weight gain is directly
associated with reduced quality of life. Several limitations
of this study were previously noted [43], pointing particu-
larly to a major confounding factor: most of the
respondents started their antipsychotic medications sev-
eral years before the survey. Because antipsychotics differ
in the magnitude and in the trajectory of weight gain over
time [44], the reported differences may reflect differences
between a group of patients whose illness is well managed
and thus are reporting a sense of relative psychological
well being and a group of distressed patients who are
adjusting to a new antipsychotic regimen [43]. The other
survey [45] queried depressed psychotic patients who
called a mental health crisis line about the impact of eight
adverse events, including weight gain, on their emotional
distress and satisfaction with treatment. Although weight
gain was the adverse event reported least, it was viewed as
the most distressing, particularly for women, and was
linked to lower satisfaction with treatment. This survey,
which was noted for its lack of rigorous design [2], did not
report the treatment duration on the antipsychotic drugs.
Resultantly, the respondents may have started the antipsy-
chotic regimens years before the survey, obscuring the
findings in a manner similar to that in the survey by Alli-
son and colleagues [42].
In essence, the two retrospective self-reports appear to
have assessed patients' treatment satisfaction and percep-
tions rather than objective parameters of clinical change
and treatment progress. Studies that objectively measure
weight change and clinical response in a prospective fash-
ion are more desirable as they provide more objective
information. This is especially important because retro-
spective self-reports may capture the social climate rather
than objective changes in clinical outcomes. It is notewor-
thy, however, that there are four prospective studies
reporting findings that are inconsistent with ours [6-9].
The reasons for the inconsistencies are not clear but may
be due to small sample size. The sample size needed to
detect a correlation of .20 with 80% power is 194, while
sample sizes for these four studies ranged from 30 to 82.
Although the current study found a link between treat-
ment-emergent weight gain and better therapeutic
response, its correlational nature does not allow for dis-
cerning the underlying causes. There are numerous factors
and poorly understood mechanisms that may impact
patients' weight gain during treatment, including environ-
mental, behavioral, neurochemical, genetic, and clinical
factors [17]. It was previously noted, for example, that the
association between weight gain and therapeutic
improvement may reflect for some patients the restora-
tion of body weight lost during an acute episode because
patients were previously found to restore their original
Table 3: Conditional probability of response given different amounts of weight gain for all patients and by medication
Olanzapinea Haloperidolb
N = 1283 N = 622
Weight change Did not respond Respondedc P(R| W) Did not respond Respondedc P(R| W)
N% N % N% N %
Lost weight (< 0%) 210 16.4% 187 14.6% .47 176 28.3% 166 26.7% .49
Gained 0 to < 3% 118 9.2% 234 18.3% .67 88 14.2% 83 13.3% .49
Gained 3 to < 7% 111 8.7% 248 19.3% .69 39 6.3% 51 8.2% .57
Gained ≥ 7% 43 3.4% 132 10.3% .75 5 0.8% 14 2.3% .74
Note. Response was defined as a greater than 20% decrease in BPRS Core Symptoms
a Mantel-Haenszel test of linear by linear association, χ 2(1, N = 1283) = 52.3, p < 0.001.
b Mantel-Haenszel test of linear by linear association, χ 2(1, N = 622) = 4.1, p = 0.044.
cProbability of response given level of weight change.BMC Psychiatry 2005, 5:3 http://www.biomedcentral.com/1471-244X/5/3
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body weight upon recovery, even prior to the introduction
of antipsychotics [46].
While the association between treatment-emergent
weight gain and therapeutic response may be due to spe-
cific pharmacological pathways, it is also possible that
non-pharmacological pathways play an important role.
The link between weight gain and therapeutic response
may be an epiphenomenon that accompanies clinical and
functional improvements by influencing patients'
increased motivation, pleasures, and specific behaviors
that enhance weight gain [16]. Future studies will be
needed to evaluate the correlations reported here in order
to better understand the underlying mechanisms of treat-
ment-emergent weight gain, and help differentiate phar-
macological from non-pharmacological pathways to
weight gain in the treatment of schizophrenia with antip-
sychotics. A promising research strategy [47] may involve
the use of placebo-controlled trials of antipsychotics to
contrast weight change between patients who improved
on placebo with those who deteriorated on placebo. It is
important to note that regardless of the pathways to
weight gain, the link between excess weight and greater
morbidity and mortality calls for careful clinical attention
during the treatment of patients with schizophrenia.
Another important issue that needs addressing is the
growing focus on the associations between obesity and
poorer quality of life among schizophrenia patients [48].
Such research helps highlight the need to distinguish
between treatment-emergent weight gain and obesity.
Although these terms are not mutually exclusive, they are
not synonymous either. Gaining weight during treatment
with antipsychotics should not be equated with becoming
obese. For example, thin individuals may gain a poten-
tially clinically meaningful proportion of their baseline
body weight (≥ 7%) and attain an average BMI, whereas
obese individuals may gain the same proportion of their
baseline weight but maintain their initial obese status per
BMI categorization. There are numerous permutations to
this phenomenon, suggesting the need to recognize its
complexity and pursue further studies that may help clar-
ify the causes and the consequences of treatment-emer-
gent weight gain among individuals with schizophrenia
who differ in their baseline body weight.
The current study has its limitations. First, it examined
weight change post-hoc and only during the acute phase
of the illness, which was confined to the first 6 weeks of
treatment, and the findings may not generalize to long-
term treatment-emergent weight gain. It is noteworthy
that this study assessed treatment-emergent weight gain at
6-weeks, although patients continue to accrue weight
beyond the acute treatment phase. For olanzapine-treated
patients, the mean weight gain observed at 6-weeks (2.0
kg) was about a third of 6.26 kg mean weight gain found
at 39 weeks, when weight gain tends to plateau on olan-
zapine [49]. Similarly, the haloperidol-treated patients
had a 0.3 kg mean weight gain at 6 weeks, which was less
than half of 0.69 kg mean weight gain observed for these
patients after 39 weeks of treatment. This observation
highlights the need to assess the association between
weight gain and treatment outcomes in longer-term stud-
ies. The choice of 6-weeks was not only driven by the
design of the study, in which treatment responders in the
acute phase were followed up in the 46-week mainte-
nance period of the study, but also by the clinical rele-
vance of the acute treatment phase. Clinicians often use
the first 6-weeks of treatment to assess the tolerability and
effectiveness of a new antipsychotic regimen and to decide
whether to continue or discontinue that course of therapy
[15]. Further, the study of the first 6 weeks of treatment
enabled comparisons of the current findings with other
studies, which were typically of short-term duration.
Although weight gain appears to be greatest and most
rapid during the first 6 weeks of treatment with clozapine
[16], and during the first 12 weeks for olanzapine with a
trend toward a plateau after approximately 39 weeks of
treatment, [49] longer-term studies will be needed to
determine the validity of the current findings in longer-
term treatment. This may be, however, difficult to study.
Patient attrition from studies is not random, with those
experiencing poor treatment efficacy or poor tolerability
being more likely to discontinue the study, leaving a rela-
tively homogeneous group of study completers who are
also treatment responders. Such reduction in the variabil-
ity of treatment outcomes may diminish the likelihood of
finding this phenomenon in long term randomized dou-
ble blind studies. Further, if this phenomenon were to be
investigated in long-term naturalistic observational stud-
ies, one would likely face another problem, namely the
prevalent use of polypharmacy [50], and the dynamic
nature of treatment for schizophrenia, [51] with frequent
changes in antipsychotic regimens and in concomitant
psychotropic medications. Such complexity may increase
the difficult in identifying which treatment at what time
was associated with which weight gain and treatment
outcome.
It is of interest to note, however, that despite rapid weight
gain during the 6-week period in our study, when weight
gain is more likely to be noticed by the patients and their
clinicians and thus may elicit a negative emotional
response, the weight gain in this study was not only linked
to improved clinical and functional status but also to
reduced emotional distress as measured by the depression
scales.BMC Psychiatry 2005, 5:3 http://www.biomedcentral.com/1471-244X/5/3
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Another limitation of the study is its lack of assessment of
patients' adherence with medication. It is possible that
weight gain and improvement occurred together because
improvements occur mostly in patients who are medica-
tion adherent. Although this was not assessed in the
present study, this possibility was previously studied by
Meltzer et al. [16], who found a significant association
between clozapine-emergent weight gain and improved
psychopathology. In their study, non-adherent patients
were expected to have lower or absent plasma clozapine
levels, but there was no relationship between plasma cloz-
apine levels and weight gain or clinical response. Meltzer
and colleagues also monitored adherence closely during
weekly visits to determine white blood count and found
no evidence of intermittent or poor adherence in their
study patients. Additionally, the associations between
weight gain and improved outcomes in our study were
similarly found within the haloperidol and within the
olanzapine treatment groups when controlling for treat-
ment duration. Treatment duration is a proxy for time on
the medication in randomized double-blind trials, where
treatment discontinuation for any reason results in
patient's discontinuation from the study. Thus, if patients
were more adherent with one antipsychotic drug than
with the other, and medication adherence influenced the
associations between weight gain and outcomes, then one
would expect to find the association between weight gain
and improved outcomes to be present only in the more
adherent treatment group, but not in both treatment
groups, as found in the present study.
Another study limitation is the correlational nature of the
analyses, which precludes cause-effect relationship and
allows for the possibility that the observed associations
might be due to an unobserved variable or set of variables.
Further, the relatively low correlations suggest that the
association explains only a small proportion of the vari-
ance in treatment outcomes. Response to antipsychotic
medications is a complex phenomenon that is associated
by numerous relatively independent components [16]
and weight gain is only one of them. Nonetheless, this
link was demonstrated when using other statistical
approaches, including contrasting of weight gains
between responders and patients who did not respond, by
identifying the degree of improvement associated with
every 1-kg gained at 6 weeks, and by calculating the con-
ditional probability of therapeutic response given various
amounts of weight gain. These findings are important as
they suggest that acute weight gain is a valuable prognos-
tic marker in the treatment of schizophrenia.
Next, because the study included patients with a moder-
ately severe level of symptomatology, the current findings
may not generalize to patients with milder or residual
symptoms of schizophrenia. However, the relationships
among the severity of patients' baseline symptomatology,
treatment-emergent weight gain and therapeutic response
is currently unclear. And lastly, this study used the SF-36,
a self-report measure of functional status, which was not
designed to assess the potential impact of weight gain on
patients' functional status or quality of life. Preliminary
information on the first measure designed to specifically
capture the impact of antipsychotic-emergent weight gain
on patients' psychosocial functioning was only recently
published [52]. One would have expected, however, to
detect a decline in patients' mental or physical levels of
functioning if the experienced weight gain were to have
adverse impact during the acute treatment phase.
Conclusions
Women (and men) with schizophrenia who gained
weight during treatment with olanzapine or haloperidol
did not experience worsening of clinical or functional sta-
tus. To the contrary, they had significant improvements in
core symptoms of schizophrenia, depressive symptoms,
and mental and physical level of functioning. Although
excessive weight gain, regardless of origin, is of concern
due to its association with physical health problems, the
current findings suggest that patients who have greater
treatment-emergent weight gain are more likely to benefit
from treatment with olanzapine or haloperidol. Findings
highlight the complexity inherent in medication manage-
ment of schizophrenia patients and the need to balance
treatment risks and benefits for each patient. In addition,
further prospective studies will be required to assess the
effects of weight gain, in both psychiatric and medical
terms, on individuals treated for schizophrenia with vari-
ous antipsychotic medications.
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